AKCA

Akcea Therapeutics Inc

NASDAQ

Add Alert

AKCA

Akcea Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Sidney

03/29/18 2:44 PM

Post #19

Any thoughts on why so low today?

Thoro

08/31/17 2:10 PM

Post #18

So Volatile. Any thoughts on why the big plunge today?

Rodney213

08/08/17 9:58 PM

Post #17

Like how clean the board is .Some heavy price target coverage today

dinosaurbob Free

08/04/17 5:27 PM

Post #16

Re: #15: @Thoro - This is a volatile stock. Its finding

Dropped heavy yesterday but bounced back some today. I am still up 17%, so I am not complaining.

Thoro

08/03/17 4:44 PM

Post #15

Re: #14: @dinosaurbob - Closed at $15.43 today up 47 cents.

This is a volatile stock. Its finding its legs.

dinosaurbob Free

08/02/17 6:14 PM

Post #14

Closed at $15.43 today up 47 cents.

dinosaurbob Free

07/31/17 4:48 PM

Post #13

Back up $1.02 today. This stock is like riding a roller coaster. Up one day and down the next. And big drops and rises too.

dinosaurbob Free

07/28/17 5:24 PM

Post #12

WTH happened today? Down $1.52!

dinosaurbob Free

07/27/17 7:32 PM

Post #11

Closed up 40 cents at $14.88

dinosaurbob Free

07/27/17 2:47 PM

Post #10

It was up big earlier but steadily dropping now. Still up 14 cents at 2:45 EST

Thoro

07/27/17 10:32 AM

Post #9

AKCA, Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency

https://ih.advfn.com/p.php?pid=nmona&article=75321782

dinosaurbob Free

07/26/17 6:31 PM

Post #8

Re: #7: @Thoro - I know it dropped, but I like when

Closed up at $14.48 (5.16%). Nice!

Thoro

07/26/17 12:57 AM

Post #7

Re: #6: @dinosaurbob - Yes, but it dropped to $13.77. I

I know it dropped, but I like when it tests higher.

dinosaurbob Free

07/25/17 5:08 PM

Post #6

Re: #5: @Thoro - AKCA $16.30 looked great today!

Yes, but it dropped to $13.77. I still believe in it though.

Thoro

07/25/17 5:01 PM

Post #5

Re: #4: @dinosaurbob - I bought in at 9.88 and then doubled

AKCA $16.30 looked great today!

dinosaurbob Free

07/23/17 3:24 AM

Post #4

Re: #3: @Thoro - AKCA IPO doing great first 5 days of trading.

I bought in at 9.88 and then doubled my portfolio Friday at $13.00. I see this over $20.00 by October!

Thoro

07/21/17 2:48 PM

Post #3

AKCA

IPO doing great first 5 days of trading.

Thoro

07/17/17 12:57 PM

Post #2

AKCA

#MARKET NEWS
JULY 14, 2017 / 12:12 PM / 3 DAYS AGO
BRIEF-Akcea Therapeutics Inc shares open at $8.13 in debut vs IPO price of $8/share

http://www.reuters.com/article/brief-akcea-therapeutics-inc-shares-open-idUSFWN1K50CZ

Thoro

07/17/17 12:55 PM

Post #1

AKCA

#MARKET NEWS
JULY 13, 2017 / 8:30 PM / 4 DAYS AGO

BRIEF-Akcea Therapeutics says public offering of 15.6 mln common shares priced at $8 per share

http://www.reuters.com/article/brief-akcea-therapeutics-says-public-off-idUSASA09X2O

Akcea Therapeutics Inc (AKCA)

Followers	4	Posters	4
Posts (Today)	0	Posts (Total)	19
Created	07/17/17	Type	Free
Moderators

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Each of the four drugs in the Company's pipeline targets the specific ribonucleic acid, or RNA, that encodes for a unique protein associated with lipid dysfunction, robustly and selectively inhibiting the production of such protein. Additionally, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx utilize Ionis' advanced Ligand Conjugated Antisense (LICA) technology. The Company has completed a Phase I/II study with AKCEA-APO(a)-LRx in patients with hyperlipoproteinemia(a). The Company is engaged in developing AKCEA-ANGPTL3-LRx to treat multiple lipid disorders. The Company is engaged conducting a Phase I/II program for AKCEA-ANGPTL3-LRx in people with elevated triglycerides. The Company is also engaged developing AKCEA-APOCIII-LRx to inhibit the production of ApoC-III, the same protein inhibited by volanesorsen, for the broad population of patients having cardiometabolic disease due to their elevated triglyceride levels. The Company is engaged conducting a Phase I/II study of AKCEA-APOCIII-LRx.

The Company competes with uniQure N.V., Regeneron Pharmaceuticals, Inc. and Gemphire Therapeutics, Inc.http://www.reuters.com/finance/stocks/overview?symbol=AKCA.O

More Information:
http://www.reuters.com/finance/stocks/overview?symbol=AKCA.O

Address
55 Cambridge Pkwy Ste 100
CAMBRIDGE, MA 02142-1219
United States - Map
+1-760-6032732 (Phone)
+1-302-6555049 (Fax)